Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

38 results about "Regulon" patented technology

In molecular genetics, a regulon is a group of genes that are regulated as a unit, generally controlled by the same regulatory gene that expresses a protein acting as a repressor or activator. This terminology is generally, although not exclusively, used in reference to prokaryotes, whose genomes are often organized into operons; the genes contained within a regulon are usually organized into more than one operon at disparate locations on the chromosome. Applied to eukaryotes, the term refers to any group of non-contiguous genes controlled by the same regulatory gene.

Process for the biological production of 1,3-propanediol with high titer

The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor and a 1,3-propanediol oxidoreductase (dhaT). The dramatically improved process relies on the presence in E. coli of a gene encoding a non-specific catalytic activity sufficient to convert 3-hydroxypropionaldehyde to 1,3-propanediol.
Owner:DUPONT US HLDG LLC

Novel Recombinant BCG Tuberculosis Vaccine Designed to Elicit Immune Responses to Mycobacterium Tuberculosis in all Physiological Stages of Infection and Disease

A vaccine against Mycobacteria tuberculosis (Mtb) is provided. The vaccine comprises a recombinant Bacille Calmette-Guerin (BCG) subunit-based vaccine in which one or more Mtb antigens and one or more Mtb resuscitation or reactivation antigens are overexpressed, and in which at least a portion of the DosR regulon is up-regulated. The vaccine is protective against active Mtb infection both pre- and post-exposure to Mtb, and thus prevents disease symptoms due to the recurrence of a latent Mtb infection.
Owner:INT AIDS VACCINE INITIATIVE INC

Method for identifying genes that are upstream regulators of other genes of interest

There is provided a method for identifying genes that regulate the expression of other genes, by placing a sample containing genetic material in a section of a grid, silencing expression of at least one predetermined gene in the sample, grown in the section of the grid, so that in each section of the grid at least one predetermined gene is silenced, determining the amount of genetic material of interest is present in each section of the grid, and identifying the sections of the grid in which the silencing was maximal thereby identifying genes that regulate the expression of other genes and the genes of interest identified by the method. Also provided by the present invention is a kit for performing the above method, the kit having a grid for holding a sample, inactivating agents for inactivating genetic material in the sample, and a measuring device for measuring the inactivation of the genetic material.
Owner:MINC GOLOMB DAHLIA

Kit for detecting regulon of Leber disease and use thereof

InactiveCN102747152ARelieve painSolve the problem of extracting DNAMicrobiological testing/measurementPositive controlMitophagy
The invention provides a kit for detecting mitochondrial DNA mutation related to a regulon of a Leber disease, wherein the kit consists of primer sequences, reagents for extracting genome DNA of samples, reagents for PCR amplification reaction, a positive control sample, a negative control sample and an instruction, restrictive endonucleases comprise a restrictive endonuclease Nla III, and the positive control sample is a restriction enzyme digested sample in which 4435th site of a mitochondrial sequence occur A to G mutation. The kit provided by the invention can be applied in the detection of mitochondrial DNA mt DNAA4435G mutation related to the regulon of the Leber disease. According to the kit, specificity and stability of detection results can be ensured, cost is lower than that of other detection methods, and the detection process is simple, quick, accurate and economic, and thus is suitable for detecting LHON-related gene mutation.
Owner:ZHEJIANG UNIV

Methods and compositions for promoting thermogenic potential

The invention provides methods and compositions relating to molecular targets identified as being capable of increasing or decreasing thermogenic potential in cells, including preadipocytes. Included in the invention are methods and compositions relating to inhibiting or suppressing the activity of an uncoupling protein 1 (UCP1) negative regulator, such as cardiac actin 1 (ACTC1), somatostatin receptor 1 (SSTR1), FAT atypical cadherin 1 (FAT1), and protein tyrosine phosphatase receptor type B (PT-PRB). Also included in the invention are methods and compositions relating to activating a UCP1 positive regulator, such as phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 (PREX1), cortactin binding protein 2 (CTTNBP2), doublesex and mab-3-related transcription factor-like family A1 (DMRTA1), and endothelin receptor type B (ENDRB). The invention also provides methods and compositions relating to enrichment of cells having thermogenic potential based on cell surface markers, e.g., CD29, identified as being predictive of such.
Owner:JOSLIN D ABETES CENTER INC

Method for methanol independent induction from methanol inducible promoters in Pichia

The present invention relates to a method for producing a polypeptide in a methylotrophic yeast host cell, wherein expression of the polypeptide is controlled by a methanol inducible promoter, comprising: i) expression of a positive regulator from a non-native promoter, said positive regulator activating transcription from the methanol inducible promoter, and ii) no addition of methanol.
Owner:NOVOZYMES AS

Generation of new bcg vaccine strains protecting against the establishment of latent mycobacterium tuberculosis infection and reactivation from the latent or persistent state

A vaccine for treating or preventing the establishment of latent tuberculosis infections is provided. The vaccine comprises a recombinant mycobacterium that overexpresses the transcription factor DosR, at a level sufficient to induce production of the dosR regulon genes or proteins. A host to whom the vaccine is administered mounts an immune response to the dosR regulon proteins and is thus protected from the establishment, persistence or reactivation of latent tuberculosis.
Owner:INT AIDS VACCINE INITIATIVE INC +1

Tuberculosis vaccines including recombinant bcg strains overexpressing phop, and/or phop regulon protein(s)

A live recombinant Mycobacterium bovis-BCG strain comprising a nucleic acid encoding PhoP protein and / or one or more phoP regulon proteins is provided, in which the nucleic acid is capable of being overexpressed. A vaccine or immunogenic composition comprising the live recombinant Mycobacterium bovis-BCG strain and a method for treatment or prophylaxis of a mammal against challenge by Mycobacterium tuberculosis or Mycobacterium bovis are also provided.
Owner:成都安永鼎业生物技术有限公司

Method for production of an l-amino acid

A method is provided for producing an L-amino acid by culturing a microorganism belonging to the Enterobacteriaceae family and having the ability to produce an L-amino acid, in a medium to produce and accumulate the L-amino acid in the medium. The microorganism has been modified by introduction of a DNA fragment which includes a pho regulon promoter and a structural gene encoding an L-amino acid biosynthetic enzyme, which is ligated downstream of the promoter so that the gene is expressed by the promoter, and so that the activity of the L-amino acid biosynthetic enzyme is increased by the expression of the gene by the promoter. In this way, the L-amino acid that is produced in the medium can be collected. Furthermore, the phosphorus concentration in the medium is such that the expression of the gene by the promoter is induced.
Owner:AJINOMOTO CO INC

Haemophilus influenzae type IV pili

The invention described herein relates to a Haemophilus influenzae (H. influenzae) regulon encoding type IV pili. In particular, the invention relates to type IV pili from nontypeable H. influenzae (NTHi) and from H. influenzae strains a, b, c, e and f. The invention provides isolated H. influenzae pilus polynucleotides and polypeptides encoded by the polynucleotides as well as polynucleotides and polypeptides encoded by the polynucleotides involved in the assembly / disassembly of the structure. The invention also relates to uses of these polynucleotides and / or polypeptides including methods for eliciting an immune response to H. influenzae and methods of treating and preventing H. influenzae related pathological conditions.
Owner:NATIONWIDE CHILDRENS HOSPITAL

Methods for the identification of inhibitors of an isoprenoid metabolic pathway

The present invention relates to methods of identifying genes whose expression is indicative of activation of a particular biochemical or metabolic pathway or a common set of biological reactions or functions in a cell (“regulon indicator genes”) The present invention provides an example of such an indicator gene. The present invention also relates to methods of partially characterizing a gene of unknown function by determining which biological pathways, reactions or functions its expression is associated with, thereby placing the gene within a functional genetic group or “regulon”. These partially characterized genes may be used to identify desirable therapeutic targets of biological pathways of interest (“regulon target genes”) The present invention provides examples of such target genes. Methods for identifying effectors (activators and inhibitors) of regulon target genes are provided. The present invention also provides examples of regulon target gene inhibitors.
Owner:MERCK & CO INC

Oxidation and high salt stress resistant artificially synthesized sRNA and application thereof

A core sequence fragment from a pseudomonas stutzeri non-coding sRNA gene is discovered and determined for the first time by the invention, and the core sequence fragment is combined with the transcriptional regulon Hfq of an escherichia coli non-coding RNA to synthesize a novel sRNA artificially. Experiments show that the artificially synthesized sequence endows a host cell with an oxidation and high salt stress resisting function.
Owner:北京绿氮生物科技有限公司

Tumor angiogenesis regulatory protein TARBP2, and encoding gene and application thereof

According to the invention, with tumor angiogenesis as a starting point, a protein TARBP2 and a coding gene thereof are identified to be novel tumor angiogenesis regulators and can specifically degrade mRNAs of anti-angiogenesis factor genes to induce tumor angiogenesis and promote tumor metastasis. The adenovirus vector expressing shRNA targeting TARBP2 is used for treating tumors and can significantly inhibit tumor angiogenesis, metastasis and growth. The tumor angiogenesis regulatory protein and the encoding gene thereof provided by the invention provide a novel molecular target for targeting tumor angiogenesis to treat tumors, and have important theoretical and practical significance for clinically resisting angiogenesis to treat the tumors in the future.
Owner:INST OF MICROCIRCULATION CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE

Nucleic protein 'Shoca'-a component of wnt signal transmission channel

An isolated Shoca polypeptide comprising: (i) the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 4; or (ii) a variant thereof which is capable of interacting with a polypeptide of the wnt signalling pathway; or (iii) a fragment of (i) or (ii) which is capable of interacting with a polypeptide of the wnt signalling pathway, a polypeptide encoding said polypeptide, a method for identifying a modulator of the wnt signalling pathway utilising said polypeptide or polynucleotide and methods of diagnosing and treating cancer.
Owner:THE UNIV CHILDRENS HOSPITAL OF BOTH CANTONS OF BASEL

Cyclic AMP response element activator proteins and uses related thereto

The present invention discloses newly identified cyclic AMP response element activator proteins (CREAP proteins). It is mentioned herein that the protein is a suitable drug target for developing new therapeutic agents to prevent, treat or alleviate pathological conditions related to abnormal activation of CRE-dependent gene expression or abnormal activation of chemokines. The present invention relates to a method for preventing, treating or alleviating said pathological conditions and a pharmaceutical composition comprising a regulator having an inhibitory effect on CREAP protein activity and / or CREAP gene expression. The present invention also relates to methods of identifying compounds useful in the treatment of said pathological conditions, comprising identifying compounds capable of inhibiting CREAP protein activity and / or CREAP gene expression.
Owner:NOVARTIS AG

Single-stranded antimicrobial oligonucleotides and uses thereof

The current invention is directed to oligonucleotide sequences isolated from a sequence designated rbl-1 [SEQ ID NO. 19] that either kill or inhibit growth, or prevent the production of endogenously expressed toxin, of microorganisms. These ssDNA sequences, identified through use of a screening method, appear to act as modulators of essential growth functions which may act at the level of triplex formation, antisense inhibition, or as aptamers that alter gene function. The sequences, referred to as minimum functional regions, or MFRs, are useful inter alia as therapeutic agents for treatment of sepsis and other pathologies caused by microorganisms such as sepsis and / or in which microorganisms are contributory agents.
Owner:CYTOGENIX INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products